Middle East And Africa Veterinary Pharmaceutical Market - Strategic Insights and Forecasts (2026-2031)

The Middle East and Africa veterinary pharmaceuticals market is forecast to grow at a CAGR of 6.1%. It is projected to reach USD 469.2 million in 2031, significantly increasing from USD 348.7 million in 2026.

Key demand drivers include the intensification of commercial livestock production due to rising protein demand, coupled with governmental food security mandates to protect national livestock assets. Additionally, increasing pet ownership and sophistication in companion animal care, particularly in GCC countries, is boosting demand for specialty pharmaceuticals.

Regulatory influence is increasing, with authorities like the SFDA and EDE implementing stricter traceability and antimicrobial resistance (AMR) guidelines. Furthermore, regulatory harmonization efforts in SADC and EAC regions are standardizing drug registration dossiers, which actively reduces market entry barriers for multinational manufacturers.

Local capacity in Saudi Arabia, Egypt, and South Africa is expanding, with Saudi Arabia's Vision 2030 creating localized manufacturing opportunities. Pet care sophistication and increased spending on preventive care are particularly notable in urbanized populations of the UAE and Saudi Arabia, while sub-Saharan Africa faces cold-chain constraints.

Major opportunities include incentives for localized manufacturing, such as Saudi Arabia’s Vision 2030, allowing domestic firms to capture market share. Key restraints include inadequate cold-chain infrastructure in sub-Saharan Africa limiting biologics distribution, and new AMR regulations in the UAE and Kenya restricting over-the-counter antibiotic sales.

The 'One Health' approach is of strategic importance, directly linking animal health to human public health outcomes and economic stability. Recurring outbreaks of zoonotic diseases like Rift Valley Fever and Avian Influenza compel governments to mandate national vaccination programs for production animals, driving pharmaceutical demand.